Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation

Sponsor
Yinglong Hou (Other)
Overall Status
Recruiting
CT.gov ID
NCT06119802
Collaborator
(none)
10,000
1
27.9
358.1

Study Details

Study Description

Brief Summary

To clarify the predictive effects of uric acid and superoxide dismutase as biomarkers of oxidative stress on atrial fibrillation, and to provide greater value for the diagnosis and prediction of atrial fibrillation. It provides a new idea for the prevention and treatment of atrial fibrillation.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: atrial fibrillation

Detailed Description

In recent years, a growing number of reports have shown the importance of oxidative stress in the pathophysiological mechanism of AF. During oxidative stress, there is an imbalance between the production of pro-oxidant reactive species and the antioxidant defenses of the cell, and excessive oxidation leads to oxidative damage and cell death. Redox processes can lead to atrial fibrosis and cardiac remodeling , suggesting that strategies to address myocardial oxidative stress may constitute a reasonable approach for the treatment of AF. However, few studies have reported the relationship between comprehensive oxidative stress-related biomarkers and AF. The purpose of this study was to illuminate the relationship of several blood markers of oxidative stress with AF and to provide new clues for the prevention and treatment of AF.

Study Design

Study Type:
Observational
Anticipated Enrollment :
10000 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Oct 31, 2023
Anticipated Study Completion Date :
Apr 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Atrial Fibrillation cohort

The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF. The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate <30 ml/ (min*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.

Diagnostic Test: atrial fibrillation
ECG of atrial fibrillation last more than 30 seconds.

Non-atrial Fibrillation cohort

Patients attending the Department of Cardiology to rule out atrial fibrillation.The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate <30 ml/ (min*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.

Outcome Measures

Primary Outcome Measures

  1. Uric acid/SOD ratio is associated with atrial fibrillation [3 years]

    Uric acid/SOD ratio is associated with atrial fibrillation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria: This retrospective study enrolled all hospitalized patients from January 2018 to December 2020 at the Department of Cardiology in The First Affiliated Hospital of Shandong First Medical University. The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF.

Exclusion Criteria:
  1. acute heart failure and acute myocardial infarction;

  2. severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate <30 ml/ (min*1.73 m2));

  3. malignant tumors;

  4. missing data of laboratory indicators at baseline.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shandong provincal Qianfoshan hospital Jinan Shandong China 250014

Sponsors and Collaborators

  • Yinglong Hou

Investigators

  • Study Chair: Hui Tian, PhD, Qianfoshan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yinglong Hou, professor, Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT06119802
Other Study ID Numbers:
  • YXLL-KY-2023(044)
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yinglong Hou, professor, Qianfoshan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023